Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Current Liabilities (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Total Current Liabilities for 13 consecutive years, with $106.3 million as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 443.22% year-over-year to $106.3 million; the TTM value through Mar 2026 reached $106.3 million, up 443.22%, while the annual FY2025 figure was $76.7 million, 179.67% up from the prior year.
  • Total Current Liabilities hit $106.3 million in Q1 2026 for Viking Therapeutics, up from $76.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $106.3 million in Q1 2026 and bottomed at $11.3 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $29.1 million, with a median of $21.9 million recorded in 2022.
  • Year-over-year, Total Current Liabilities tumbled 40.28% in 2025 and then surged 443.22% in 2026.
  • Viking Therapeutics' Total Current Liabilities stood at $21.9 million in 2022, then dropped by 12.81% to $19.1 million in 2023, then surged by 43.26% to $27.4 million in 2024, then soared by 179.67% to $76.7 million in 2025, then surged by 38.68% to $106.3 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $106.3 million, $76.7 million, and $26.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.